Shots:

• Sitryx to receive $50M upfront- $10M equity investment- ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies- including Sitryx's two lead projects
• The companies will collaborate for 5yrs. supporting the development of therapies with Sitryx to be responsible for drug discovery while Lilly to fund and manage the clinical & commercial activities
• The collaboration will evaluate up to four novel preclinical targets identified by Sitryx- leading to potential therapies for autoimmune diseases

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Luckystep